PMID-27450736 – Cardioprotection by Thymosin Beta 4
Pipes GT et al. "Cardioprotection by Thymosin Beta 4," Vitamins and Hormones, 2016;102:209-239. doi:10.1016/bs.vh.2016.04.004
Quick Reference
| Property | Value |
|---|---|
| PMID | 27450736 |
| DOI | 10.1016/bs.vh.2016.04.004 |
| Year | 2016 |
| Journal | Vitamins and Hormones |
| Study Type | Narrative Review |
| Evidence Level | V |
| Sample | Review of preclinical cardiac studies |
| Peptide(s) Studied | TB-500 |
Key Findings
- Tβ4 reduces infarct volume and preserves cardiac function in ischemic injury models
- Activates epicardial progenitor cells for cardiac regeneration
- Promotes neovascularization in the ischemic myocardium
- Exerts antifibrotic effects, preventing pathological remodeling
- Expressed during embryonic cardiac development; adult re-administration recapitulates developmental repair programs
Study Design
Authoritative narrative review synthesizing the preclinical evidence for Tβ4 in cardioprotection. Covers molecular mechanisms, animal model data, and translational potential.
Limitations
- All evidence is preclinical; no human cardiac trial data
- Mechanisms may be species-specific (mouse vs. human heart regeneration capacity differs substantially)
Clinical Relevance
Provides the mechanistic framework for understanding Tβ4's cardiac applications. The activation of epicardial progenitors is a unique mechanism not shared by other recovery peptides. Relevant for understanding TB-500's potential beyond musculoskeletal healing.
Related
#research #narrative-review #evidence-level-V